Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways-Reference-Cited by-同舟云学术

Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways

Published:2016-09-28 Issue: Volume:7 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Ermisch Michael,Bucsics Anna,Vella Bonanno Patricia,Arickx Francis,Bybau Alexander,Bochenek Tomasz,van de Casteele Marc,Diogene Eduardo,Fürst Jurij,Garuolienė Kristina,van der Graaff Martin,Gulbinovič Jolanta,Haycox Alan,Jones Jan,Joppi Roberta,Laius Ott,Langner Irene,Martin Antony P.,Markovic-Pekovic Vanda,McCullagh Laura,Magnusson Einar,Nilsen Ellen,Selke Gisbert,Sermet Catherine,Simoens Steven,Sauermann Robert,Schuurman Ad,Ramos Ricardo,Vlahovic-Palcevski Vera,Zara Corinne,Godman Brian

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference62 articles.

1. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers;Adamski;BMC Health Services Res.,2010

2. Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EU;Annemans;J. Comp. Effectiv. Res.,2012

3. Trial watch: phase III and submission failures: 2007-2010;Arrowsmith;Nat. Rev. Drug Disc.,2011

4. Accelerated access to innovative medicines for patients in need;Baird;Clin. Pharmacol. Therap.,2014

5. Approvals of drugs with uncertain benefit-risk profiles in Europe;Banzi;Eur. J. Inter. Med.,2015

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical development of anticancer drugs can be enhanced using efficacy data of small population clinical trials;Journal of Clinical Pharmacy and Therapeutics;2022-05-07

2. Building HTA insights into the drug development plan: Current approaches to seeking early scientific advice from HTA agencies;Drug Discovery Today;2022-01

3. The value of anticancer drugs — a regulatory view;Nature Reviews Clinical Oncology;2021-12-06

4. Current landscape of clinical development and approval of advanced therapies;Molecular Therapy - Methods & Clinical Development;2021-12

5. Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England;Value in Health;2021-12